When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
HGEN - Late-stage study of Humanigen's lead drug in COVID-19 to continue unchanged
Humanigen Inc.
The Independent Data Safety Monitoring Board (DSMB) has completed pre-specified interim analysis for Humanigen's (OTCQB:HGEN) lead drug candidate lenzilumab Phase 3 trial for COVID-19 and recommended that the study continue unmodified.
More news on: Humanigen, Inc., Healthcare stocks news,